Investor Relations
- We welcome 2 new acquisitions to the Swedencare family –
Nutravet & Animal Pharm (24 Sept 2020): (Print)
CEO Comments
“A quarter characterized by a strong finish and acquisition”
— HÅKAN LAGERBERG, CEO – SWEDENCARE AB (PUBL)
SALES AND EARNINGS (Q2/2020):
Net SalesQ2 202032 015KSEK ( 5%) |
EBITQ2 20205 671KSEK (17.7%) |
Share this information:
Company Information
- Summary of the period
- Calendar
- Financial Reports
- Shares
- Presentations
- Corporate Governance
- In the Press
“A quarter characterized by a strong finish and acquisition”
SECOND QUARTER: April 1st – June 30th 2020
(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)
• Net revenue amounted to 32 015 KSEK (30 376 KSEK), a increase of 5%.
• Organic, currency-adjusted growth amounted to 0% .
• Operating profit begore depreciation (EBITDA) amounted to 7 424 KSEK (9 158 KSEK),
corresponding to a decrease of 19% corresponding to an EBITDA-margin of 23,1% (30,1%).
• Operating profit after depreciation (EBIT) amounted to 5 671 KSEK (8 657 KSEK),
corresponding to an EBIT-margin of 17,7% (28,4%), which includes an exchange rate loss of 920 KSEK.
• Profit after tax amounted to 5 145 KSEK (6 809 KSEK).
• Profit per share, based on 15 990 881 shares 0,32 SEK (0.43 SEK).
• As of June 30th 2020 cash amounted to 175 795 KSEK (39 076 KSEK).
• Costs in connection with the acquisition of Stratford’s operations amounted to 1 483 KSEK.
• Adjusted for this, EBITDA amounted to 8 907 KSEK corresponding to an EBIT-margin of 27.7%
and EBIT to 7 154 KSEK corresponding to an EBIT-margin of 22.3%.
FIRST 6-MONTHS: January 1st – June 30th 2020
(Numbers in parentheses refer to outcomes during the corresponding period of the previous year.)
• Net revenue amounted to 69 740 TSEK (60 926 TSEK), an increase of 14%.
• Organic, currency-adjusted growth amounted to 8% .
• Operating profit before depreciation (EBITDA) amounted to 17 853 TSEK (19 974 TSEK),
corresponding to a decrease of 11% corresponding to an EBITDA-margin of 25,5% (32,7%).
• Operating profit after depreciation (EBIT) amounted to 16 385 TSEK (19 335 TSEK),
and an EBIT-margin of 23.4% (31,7%).
• Profit after tax amounted to 13 586 TSEK (15 317 TSEK).
• Earnings per share calculated on 15 851 431 shares 0,86 SEK (0.97 SEK).
• Cash flow from operating activities amounted to 13 761 TSEK (15 769 TSEK).
• Foreign exchange gains amounted to 208 TSEK.
Significant events during the second quarter:
• Swedencare AB (publ) acquires operations from a leading American company in animal health care products.
• Swedencare AB (publ) appoints Håkan Lagerberg as CEO after strategic acquisition.
• Swedencare AB (publ) carries out a directed new issue of 1 500 000 shares and is thus provided with approximately 133 MSEK, which after issue costs of 4,6 MSEK gave a net contribution of 129 MSEK, to finance the American business acquisition.
Significant events after the second quarter:
• Swedencare AB (publ) took, on July 1st, over the business acquired on June 24th.
Words from the CEO:
An eventful end to Q2 and a clear change in demand in the last month of the quarter.
The second quarter’s net sales of 32 MSEK gave an increase of 5% compared to Q2 2019, while EBITDA decreased by 19% to 7,4 MSEK. Sales and earnings were affected by the Covid-19 pandemic and the profits also include approximately 1,5 MSEK in costs related to our acquisition of Stratford. Adjusted for acquisition costs, we reach an EBIT margin of 25,6% for the first half year, above our long-term goal despite a challenging environment. As the leader of a team or a company, you should be careful with concepts such as “satisfied”, but I allow myself to be proud. Our cash flow from operating activities of 14,9 MSEK also shows that we are strong even in a tough environment.
As Jenny predicted in our Q1 report, the second quarter was heavily affected by Covid-19 in the form of quarantine, closed stores, and veterinary clinics to varying degrees worldwide. We therefore had a lot of time delays in orders and sales. The fact that we came in with a small increase in sales despite an April and May which were clearly affected and the uncertainty was significant is satisfying. Despite a continued large impact worldwide, we can see that our customers have recently become more active. In the quarter, June accounted for over 40% of our sales and the sales from our subsidiaries show that the strong trend continues in July, which is why I look with confidence on the second half of 2020. Our external distributor markets will also be clearly stronger in the second half of the year, as both regular orders have been received and new products will be launched in important markets such as Japan, China, and South Korea.
In most markets, online shopping has increased strongly during the quarter as physical stores have had limited opening hours, and that there have been several restrictions for consumers to move around in the community. Our already largest customer in the US, Chewy. com, had a record quarter and accounted for over 30% of our sales in the US. Our increased market investments in the US have yielded results, we increased our sales by 28% compared to last year. It is still our powder product and the Dental Bones that are growing strongly. The UK is one of the most affected and shut down countries in Europe and there we have really seen a big change in terms of purchasing channel. During the quarter, Amazon UK continues to increase significantly, both for the reason of the expanded online initiatives and closed waiting rooms at the veterinary clinics.
As for other subsidiaries, we had record months in both Spain and Greece in June, which resulted in
a quarter of increased sales in these markets. The Nordic region also closed strongly and increased its sales by almost 50% compared to last year.Asia and Rest of the world were slightly weaker, but China is back, and we see that the second half of the year will be stronger in 2020 as we have reviewed both orders and forecasts. It feels like the world is waking up and trying to return to how it was before.
In addition to increased business operations, the final phase of the quarter was very intense for us. We resumed a discussion, which began several years ago, regarding the acquisition of Stratford Pharmaceuticals’ operations in Tampa, Florida. We managed to complete the deal on July 1st, an acquisition that changes the future of Swedencare, a so-called. “Game changer”, in my opinion. With the acquisition, we will have a channel to cover 10,000 veterinary clinics, many of whom are not customers of ours today, and we will have a business and management team that will not only develop Stratford as a subsidiary but also contribute to Swedencare’s growth worldwide.
Stratford also has an interesting product range that complements and expands our range in various parts, of which their dermatology products will be particularly interesting to launch in our distribution network worldwide. Finally, Stratford has built a unique process where they can deliver private label products to individual clinics that want their own label on their products. Without synergies and sales partnerships, as we see coming, Stratford also had an extraordinarily strong first half year with a large increase in sales and they, like us, can see that this continues in the third quarter. Therefore, their contribution to Swedencare will be clearly visible in our next quarterly report, which I am of course already looking forward to presenting!
To finance the deal and continue to have a strong financial base, we chose to carry out a directed new share issue to new and existing institutional owners. The interest was fantastic, and we welcome several new extremely reputable owners such as Robur, Berenberger and Consensus to name a few. The great interest gives us the confidence to continue to see how we can best make new steps to approach our goal of becoming the leading dietary supplement company in the world focused on pets.
In order to give the Stratford acquisition and any future acquisitions optimal conditions, the Board saw the need to strengthen the management resources. The desire was to return to the team we had before. My experience in business development and organizational building comes in handy, and that we get Jenny back as CFO was the only requirement I had, the function naturally becomes even more important after Stratford was included. Jenny and I are a collaborative and complementary team and we both look forward to developing Swedencare even faster and better. Our investment in market and brand continues with force and Sara, our global marketing manager who started working with us in the beginning of the year, has started several large projects of which some will be presented in the autumn.
In conclusion, I want to repeat that I am looking forward to writing “Words from the CEO” in future reports as we have a lot going on both in our existing business and with our new acquisition in the US.
Best summer greetings,Håkan Lagerberg, CEO
Malmö, July 24th 2020
Read the half-year report in its entirety here: (Print) (Screen)
FOR FURTHER INFORMATION:
Håkan Lagerberg, CEO
Tel: +46 (0)735-170 170, E-mail: hakan.lagerberg@swedencare.se
Jenny Graflind, CFO
Tel: +46 (0)739-448 554, E-mail: jenny.graflind@swedencare.se
Swedencare develop, produce, market and sell premium products on the global and fastgrowing market within animal healthcare for cats, dogs and horses. The product groups ProDen PlaqueOff and NutriScience are represented on approximately fifty markets in all parts of the world, including the headquarter in Malmö, six subsidiaries in the Nordics, United States, France, Spain, Great Britain and Ireland and through an external distribution network. Swedencare’s sales have increased significantly over the last few years with strong margins and results. The board of directors and the management have a wide and extensive experience of international marketing and sales.
This information is information that Swedencare AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication on July 24, 2020 08.30 CET.
Calendar Period: 2020/2021
| Date | Event |
|---|---|
| 22 October, 2020 | Interim Report Q3 2020 |
| 18 February, 2021 | Yearend Report 2020 |
| 22 April, 2021 | Interim Report Q1 2021 |
| 23 July, 2021 | Interim Report Q2 2021 |
Links to quarterly reports, annual reports
and prospectus for Swedencare AB (publ).
- Financial Reports
-
Interim reports and Quarterly presentations
- 2020
- 2019
-
2018
-
Q1
-
Reports
Presentations
Video
-
Interview with CEO Håkan Lagerberg – Q1 2018
-
-
-
Q2
-
Reports
Presentations
Video
-
Sitdown interview with CEO Håkan Lagerberg – Q2 2018
-
Company presentation with CEO Håkan Lagerberg – Q2 2018
-
-
- Q3
-
Q4
-
Reports
Presentations
Video
-
Sitdown interview with CEO Håkan Lagerberg – Q4 2018
-
Company presentation with CEO Håkan Lagerberg – Q4 2018
-
-
-
Q1
- 2017
- 2016
- Annual and Group Accounts
- Prospectus
For the current price and other share-related information,
please refer to Nasdaq First North Growth Market.
Nasdaq First North Growth Market is an alternative marketplace operated by OMX Nordic Exchange Stockholm. Companies whose shares are traded on Nasdaq First North Growth Market are not obliged to comply with the same rules as listed companies, but a less extensive regulatory framework applied to preferably smaller companies and growth companies. A placement in a company whose shares are traded on Nasdaq First North Growth Market may therefore be more risky than a placement in a listed company. All companies whose shares are traded on Nasdaq First North Growth Market have a Certified Adviser that oversees the company’s compliance with Nasdaq First North Growth Market’s regulatory framework for providing information to the market and investors. Certified Adviser reviews companies whose shares are to be traded on Nasdaq First North Growth Market. OMX Nordic Exchange Stockholm accepts the application for admission to such trade.
Click here for our current share price at Nasdaq First North Growth Market.
ISIN-code: SE0008294078
Shortname: SECARE
Certified Adviser:
FNCA Sweden AB – phone: +46(0)8 528 00 399 – Email: info@fnca.se – Address: Box 5807, 102 48 Stockholm, Sweden
Analysts and other monitoring
Dividend
Swedencare will pay a dividend that takes into account the Group’s earnings development, consolidation and investment needs,
liquidity and financial position. The goal is to pay a dividend of 40 percent of the profit after tax.
Decision on dividend
The Annual General Meeting agreed on a dividend for the financial year 2019 of 0.70 SEK per share.
Ownership
Ownership structure per latest quarterly report
| Name | Shares | Shareholding (%) |
|---|---|---|
| HÅKAN SVANBERG & CO HEALTH CARE AB | 4,631,455 | 26.77% |
| DNCA INVESTMENTS | 1,529,003 | 8,84% |
| JCC GROUP INVEST SWEDEN AB (Johan Bergdahl through bolag) | 1,517,351 | 8.77% |
| MASTAN AB (Håkan Lagerberg through bolag) | 1,110,362 | 6.42% |
| AMF AKTIEFOND SMÅBOLAG | 830,000 | 4,80% |
| SEB NANOCAP | 659,172 | 3.81% |
| SHB FONDER | 568,504 | 3.29% |
| AKTIA NORDIC MICRO CAP | 404,396 | 2.34% |
| MARTIN SHIMKO – MD Swedencare USA | 300,000 | 1.73% |
| INVESTMENT AB SPILTAN | 300,000 | 1.73% |
| JOH. BERENBERG, GOSSLER & CO. KG ACT OBO UNIVERSAL INV. FUNDS – New | 294,286 | 1.70% |
| NORDNET PENSIONSFÖRSÄKRING AB | 267,045 | 1.54% |
| CBNY-MKPGUE NAB ACF PIE GROWTH UK | 249,058 | 1,44% |
| ENTER SMÅBOLAGSFOND | 235,000 | 1,36% |
| ML, PIERCE FENNER & SMITH INC. | 222,173 | 1,28% |
| SWEDBANK ROBUR MICROCAP – New | 220,000 | 1,27% |
| HANS PERSSON – MD Swedencare France | 199,750 | 1,15% |
| TEDCAP AB (Thomas Eklund through bolag) | 190,000 | 1,10% |
| GRANDEUR, FUND BBHBOS | 170,982 | 0.99% |
| BFCM P/C BFCM SWEDEN RETAIL LT | 162,775 | 0,94% |
| CONSENSUS SMÅBOLAG – New | 142,000 | 0,82% |
| LANNEBO NANOCAP – New | 135,000 | 0,78% |
| PER MALMSTRÖM CONSULTING AB | 123,000 | 0,71% |
| AVANZA | 122,819 | 0.71% |
| FONDITA NORDIC MICRO CAP INVESTMENT – New | 117,459 | 0.68% |
| CBNY-MKJGRO NAB ACF JUNO KIWISAVER | 109,623 | 0,63% |
| AKTIA SECURA | 108,873 | 0.63% |
| COGEFI | 105,237 | 0.61% |
| Others | 2,276,657 | 13.16% |
| Total | 17,301,980 | 100% |
| Free Float* | 9,694,812 | 56,03% |
Holdings include related parties.
* Shares not owned by board members, management, their affiliates, or shareholders with more than 10%.
Ownership structure per latest month
10 Largest shareholders
| Name | Shares | Shareholding (%) | Votes (%) |
|---|---|---|---|
| HÅKAN SVANBERG & CO HEALTH CARE AB | 4,631,455 | 26.77% | 26.77% |
| JCC GROUP INVEST SWEDEN AB | 1,517,351 | 8.77% | 8.77% |
| BNP PARIBAS SEC SERV LUXEMBOURG, W8IMY | 1,409,330 | 8.15% | 8.15% |
| MASTAN AB | 1,097,352 | 6.34% | 6.34% |
| AMF AKTIEFOND SMÅBOLAG | 830,000 | 4.80% | 4.80% |
| SEB NANOCAP | 659,172 | 3.81% | 3.81% |
| HANDELSBANKEN MICROCAP SVERIGE | 494,700 | 2.86% | 2.86% |
| SIJOITUSRAHASTO AKTIA NORDIC MIC | 393,338 | 2.27% | 2.27% |
| IBKR FINANCIAL SERVICES AG, W8IMY | 356,120 | 2.06% | 2.06% |
| INVESTMENT AB SPILTAN | 300,000 | 1.73% | 1.73% |
| Others | 5,613,162 | 32.44% | 32.44% |
| Sum 2020-08-30 | 17,301,980 | 100% | 100% |
Geographical distribution
| Country | Amount of owners | Shares | Shareholding (%) | Votes (%) |
|---|---|---|---|---|
| SWEDEN | 3775 | 12,427,535 | 71.83% | 71.83% |
| LUXEMBURG | 10 | 1,698,877 | 9.82% | 9.82% |
| UNITED STATES | 15 | 1,271,855 | 7.35% | 7.35% |
| FINLAND | 57 | 768,494 | 4.44% | 4.44% |
| FRANCE | 4 | 431,560 | 2.49% | 2.49% |
| SWITZERLAND | 9 | 369,857 | 2.14% | 2.14% |
| UNITED KINGDOM | 15 | 220,260 | 1.27% | 1.27% |
| GERMANY | 4 | 35,167 | 0.20% | 0.20% |
| NORWAY | 9 | 34,954 | 0.20% | 0.20% |
| IRELAND | 6 | 11,127 | 0.06% | 0.06% |
| LIECHTENSTEIN | 1 | 11,000 | 0.06% | 0.06% |
| Other countries | 32 | 21,294 | 0.11% | 0.11% |
| Sum 2020-08-30 | 3,937 | 17,301,980 | 100% | 100% |
Holdings
| Ownership distribution by holding | Amount of owners | Shares | Shareholding (%) | Votes (%) |
|---|---|---|---|---|
| 1 – 500 | 3473 | 307,614 | 1.78% | 1.78% |
| 501 – 1000 | 212 | 169,542 | 0.98% | 0.98% |
| 1001 – 2000 | 111 | 169,762 | 0.98% | 0.98% |
| 2001 – 5000 | 56 | 184,169 | 1.06% | 1.06% |
| 5001 – 10000 | 21 | 160,151 | 0.93% | 0.93% |
| 10001 – 20000 | 11 | 164,178 | 0.95% | 0.95% |
| 20001 – 50000 | 15 | 521,335 | 3.01% | 3.01% |
| 50001 – 100000 | 10 | 759,883 | 4.39% | 4.39% |
| 100001 – 500000 | 22 | 4,720,686 | 27.28% | 27.28% |
| 500001 – 1000000 | 2 | 1,489,172 | 8.61% | 8.61% |
| 1000001 – 5000000 | 4 | 8,655,488 | 50.03% | 50.03% |
| Sum 2020-08-30 | 3937 | 17,301,980 | 100% | 100% |
Concentration
*Per 2020-08-30
| Type of Concentration | Concentration | Shareholding (%) | Votes (%) | Shares |
|---|---|---|---|---|
| The 10 largest owners | 10 | 67.56% | 67.56% | 11,688,818 |
| The 20 largest owners | 20 | 80.17% | 80.17% | 13,870,753 |
| The 30 largest owners | 30 | 87.06% | 87.06% | 15,063,346 |
Links to public presentations
of Swedencare AB (publ).
| Date | Description | Download | Video |
|---|---|---|---|
| 7 September, 2020 | Swedencare AB (publ) – Swedencare at ABGSC Investor Day 2020 |  |
|
| 2 September, 2020 | Swedencare AB (publ) – Swedencare at Pareto Securities Annual Healthcare Conference 2020 | |
|
| 10 June, 2020 | Swedencare AB (publ) – Swedencare at Handelsbanken Nordic Mid Small Cap Seminar 2020 | |
|
| 3 September, 2019 | Swedencare AB (publ) – Swedencare at Introduce Investor Days 2019 (Q2 2019) | |
|
| 3 September, 2019 | Swedencare AB (publ) – Interview with CEO Håkan Lagerberg at Introduce Investor Days 2019 (Q2 2019) | |
|
| 15 March, 2019 | Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q4 2018) | |
|
| 15 March, 2019 | Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q4 2018) | |
|
| 4 September, 2018 | Swedencare AB (publ) – Sit-down interview with CEO Håkan Lagerberg (Q2 2018) | |
|
| 4 September, 2018 | Swedencare AB (publ) – Company presentation with CEO Håkan Lagerberg (Q2 2018) | |
|
| 26 April, 2018 | Swedencare AB (publ) – Interview with CEO Håkan Lagerberg (Q1 2018) | |
|
| 20 April, 2018 | Swedencare AB (publ) – Remiums analys till institutioner, köp riktkurs 44 SEK |  |
|
| 11 September, 2017 | Swedencare AB (publ) – Investor Presentation SvD Börsplus 11 Sept 2017 | |
|
| 30 August, 2016 | Swedencare AB (publ) – Interim Report (Q2 2016) | |
|
| 21 April, 2016 | Swedencare AB (publ) – Company Presentation | |
Content
Extra bolagsstämma 2020
-2020-banner-large.jpg)
Fullmaktsformulär extra årsstämma Swedencare AB (publ)
Kallelse extra bolagsstämma Swedencare AB (publ) 20200911
Styrelsens förslag till beslut om bemyndigande – Extra bolagsstämma 20200911
Instruktioner för poströstning (Extra bolagsstämma den 11 september 2020)
Formulär poströstning (Extra bolagsstämma den 11 september 2020)
Årsstämma 2020
-2020-banner.jpg)
VD’s anförande
Styrelsens förslag – bemyndigande för styrelsen – emission av aktier
Styrelsens förslag till incitamentsprogram
Fullmaktsformulär årsstämma Swedencare AB (publ)
Kallelse årsstämma Swedencare AB (publ) 2020
Swedencare AB (publ) – Årsredovisning 2019
Legal Organization /
Board and Management.
 - Legal Organization-en_.jpg)
Swedencare
The parent company Swedencare AB (publ) is responsible for the strategy, business planning and management. This is done by the control of trademarks and patents, sales rights, cooperation agreements and as parent company of the subsidiaries. The Company and headquarter is located at Medeon Science Park in Malmö, Sweden.
Subsidiaries/Sales Company
Swedencare owns 100% of the shares to all subsidiaries/sales companies which are responsible for the sales and marketing for its individual regions. The subsidiaries provide a monthly financial report as well as a sales progress to Swedencare. The group also have a common ERP-system where orders and invoices are registered. The system enable an effective production planning at the same time as the subsidiaries can track the order progress. Through the local market knowledge of the subsidiaries the marketing can be customized and the local customer preferences and new products can easily and effectively be identified. The subsidiaries are located and managed in Greece, Spain, France, Great Britain, Ireland, Sweden and the US.
Board of Directors (BoD) and Management
The Board of Directors are responsible for the Company’s strategic and financial targets and, together with the management, for the strategic planning. In the BoD, there is an extensive experience of international sales and marketing as well as a wide international network. The Managing Director and CFO are responsible to provide a business plan in line with the BoDs strategic and financial targets. They are also responsible for financial planning, and questions and communication with the stock exchange. The CEO of the Company, together with the managing directors of the subsidiaries, is a management team responsible for product development as well as sales and marketing.
Board of Directors of Swedencare
-Board-Members.jpg)
-Board-Member-Per-Malmstrom.jpg) |
Per MalmströmPresident of the Board since 2014 – Born 1961.• Background from the financial sector, among others SEB, Aragon Fondkommission, CFO at Adera AB 1998-2001 (Addnode AB), as well as several Board assignments. Bachelor of economics from Örebro Högskola. • Managing Director and member of the board at Per Malmström Consulting AB. President of the board in K3 Nordic AB, K3 Travel AB, SVANBERG & CO INVEST AB, Creative Tools, Northway Partners, Deligate AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Hakan-Lagerberg.jpg) |
Håkan LagerbergMember of the board since 2014 – Born 1968.• International experience from leading positions in private and public companies. International Jur. Kand from Lunds University. Post graduate in International Trade Law from University of Torino in Italy. • Chairman of the Board of One CC AB. Member of the Board of Directors of Polygiene AB (publ), HAOLAG AB and Mastan AB.
Independent in relation to the company/company management: No |
-Board-Member-Johan-Bergdahl.jpg) |
Johan BergdahlMember of the board since 2014 – Born 1970.• Entrepreneur and owner to several companies within sales, IT and property management. Degree in Market economy from Nercia Business School. • President of the board in Local Market Sweden AB and BR Group AB. Member of the board in Comera AB, JCC Group AB, JCC Group Invest AB, Junikvisten 10 AB, Rostastrand Holding AB, BR Group Holding AB, BR Group Fastigheter AB, Storgatan Fastigheter AB and Trygghandel AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Tomas-Eklund_.jpg) |
Thomas EklundMember of the board since 2016 – Born 1967.
• Advisor to Patricia AB (Investor AB) and former Managing Director of Investor Growth Capital in Europe. • Board member of Boule Diagnostics AB, Biotage AB, Rodebjer Form AB and Immedica Pharma AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Hakan-Svanberg.jpg) |
Håkan SvanbergMember of the board since 2014 – Born 1957.• Entrepreneur and owner to several companies within IT, travel and finance. Master in Philosophy from Örebro University. • Managing Director in SVANBERG & CO INVEST AB. Member of the board in Creative Tools, Deligate AB, EyeonID Group AB, K3 Nordic AB, SVANBERG & CO INVEST AB, H. Svanberg Software Holding, Northway Partners, Svanberg Factoring, Treberg Holding AB, Kontosmart AB. Deputy of the board in Chief Holding AB and SWG Holding AB.
Independent in relation to the company/company management: Yes |
-Board-Member-Sara-Brandt.jpg) |
Sara BrandtMember of the board since 2019 – Born 1963.
• Vice President Almi Företagspartner, former VP and CEO Berner Nordic and before that senior positions on ia. Cederroth Nordic, Coca-Cola Sweden, Unilever Nordic and UK. Long background from international B2C and B2B companies and broad experience from several industries and product categories such as consumer health and international distributor activities.
Independent in relation to the company/company management: Yes |
* Own or related holdings of shares and other financial instruments in Swedencare. Holding by June 30, 2020.
Management
 |
Håkan LagerbergCEO• See info above.
|
 |
Jenny GraflindCFO• Jenny has been employed since 2017.
• A long international background as CFO and previously as, among other functions Financial Controller
No other assignments. |
Responsible at Swedencare’s subsidiaries
 |
John LeonardMD of subsidiaries Swedencare UK Ltd and Swedencare Ireland• John has been employed since 2004.
• Over 20 years of experience from the Oralhealth industry as Sales Manager at TePe and Colgate and development manager at CTS dental.
No other assignments. |
 |
Brian NugentMD in the subsidiary StratfordCare USA Inc• Brian has been employed since 2011.
• Over 20 years experience as founder, COO and CEO of multiple successful animal health companies based in the United States.
No other assignments. |
 |
Hans PerssonMD of the subsidiary SARL Buccosanté• Hans is employed since 2008.
• Experience of international marketing, distribution and sales as well as 25 years of experience in leading smaller companies in the French market.
No other assignments. |
__.png) |
Ioanna PsychogiouCountry Manager in the subsidiary Biovet• Ioanna has been employed since 2012.
• Background as manager of Biovet and experience in the pet and veterinary markets.
No other assignments. |
 |
Martin ShimkoMD of subsidiary SwedencareUSA Inc• Martin has been employed since 2005.
• A background as management trainee from NASSCO and the management group in The Bohle Co.
No other assignments. |
 |
Raquel ToscaCountry Manager in the subsidiary Swedencare Spain SLU• Raquel has been employed since 2019. • An international background of international business, marketing and communication at the latest from the animal health company Laboratorios Calier. Master’s degree in Marketing, Communication & Digital Publicity from UOC University in Barcelona and Inesdi Digital Business School.
No other assignments. |
 |
Sabine UhdeHead of the Nordic subsidiary Swedencare Nordic AB• Sabine has been employed since 2015.
• Background as department manager and from the marketing department on TT-line.
No other assignments. |
Articles of Association for
Swedencare AB (publ) (556470-3790)
§ 1 COMPANY NAME
The company name is Swedencare AB (publ). Public company.
§ 2 REGISTERED OFFICE
The registered head office of the company is in the municipality of Malmö.
§ 3 OBJECTS OF THE COMPANY
The company objective is, directly or indirectly, the development, manufacture and sale of products within the area of animal healthcare and preventive dental care and other business compatible therewith.
§ 4 SHARE CAPITAL
The share capital shall be not less than SEK 500,000 and not more than SEK 2,000,000.
§ 5 NUMBER OF SHARES
The number of shares shall be not less than 10,000,000 and not more than 40,000,000.
§ 6 FINANCIAL YEAR
The company’s financial year shall be calendar year.
§ 7 BOARD OF DIRECTORS
The board of directors shall consist of not less than three and not more than seven board members with not more than two deputy board members. The board members and deputy board members are elected annually for the period until the close of the first annual general meeting held after the year in which the board member or deputy board member was appointed.
§ 8 AUDITOR
For audit of the company’s annual report, the accounts and the administration of the board of directors and managing director, not less than one auditor and not more than two auditors with or without deputy auditors shall be elected.
§ 9 ANNUAL GENERAL MEETING
The following matters shall be addressed at the Annual General Meeting:
1. Election of a chairman at the meeting;
2. Preparation and approval of the voting list;
3. Election of one (1) or two (2) persons to verify the minutes of the meeting;
4. Approval of the agenda;
5. Determination of whether the meeting was duly convened;
6. Submission of the annual report and the auditor’s report, and if applicable, the group accounts and the auditor’s report for the group;
7. Resolutions:
(a) regarding the adoption of the income statement and balance sheet, and if applicable, the consolidated income statement and the consolidated balance sheet
(b) regarding allocation of profit or loss in accordance with the adopted balance sheet
(c) regarding the discharge from liability of the board members and, where applicable, of the managing director;
8. Determination of fees for the board of directors and, where applicable, for the auditors;
9. Election of the board of directors and auditors; and
10. Other matters which rest upon the meeting according to the Swedish Companies Act or the company’s articles of association.
§ 10 NOTICE TO ATTEND
Notice to attend a general meeting shall be advertised in Post- och Inrikes Tidningar (The Official Swedish Gazette) and on the company website. At the time of notice, information about the notice shall be advertised in Dagens Industri. The notice shall immediately, and at no cost for the recipient, be sent by post to those shareholders who so request and state their address.
Notice to attend an annual general meeting and notice to attend an extraordinary general meeting at which the issue of alterations of the articles of association is to be addressed shall be issued not earlier than six weeks and not later than four weeks prior to the meeting. Notice to attend an extraordinary general meeting other than such as mentioned above shall be issued not earlier than six weeks and not later than two weeks prior to the general meeting.
§ 11 APPLICATION IN ADVANCE
A shareholder, who wishes to participate at the general meeting, shall (i) be included in the transcript or other record of the share register as of five days before the meeting (ii) notify the company thereof not later than on the date specified in the notice to attend the general meeting. Such a date may not be a Sunday, other public holiday, Saturday, Midsummer Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday prior to the general meeting. If the notice to attend the general meeting does not state a last day for notification, then notification is not required in order to participate at the general meeting. A shareholder who wishes to be accompanied by advisors at a general meeting shall state the number of advisors (not more than two) accompanying the shareholder in the application.
§ 12 CSD CLAUSE
The company’s shares shall be registered in a CSD (central securities depository) register in accordance with the Financial Instruments (Accounts) Act (1998:1479).
Articles of Association adopted at the general meeting held on March 7, 2016.
Swedencare AB (publ)
Press Releases
In the Press
June 9, 2020
Investors flock to
animal companies
A growing market and investors is willing to pay dearly.
Read more »
September 3, 2019
No dark clouds
for Swedencare
Swedencare manufactures pet products, a segment that is growing large worldwide.
Read more »
August 27, 2019
Dog owners spend
more than ever
The trend remains strong worldwide and the threat of recession does not scare the pet companies. Read more »
August 6, 2019
Swedencare:
Highly rated and trendy
Animal health is a trendy subject on the stock exchange. The Swedish company Swedencare is one of the few Nordic investment alternatives on the international trend. Read more »
January 29, 2019
Swedencare’s flagship product ProDen PlaqueOff® Powder
has been awarded the VOHC® Seal of Acceptance
Two clinical studies* on dogs performed by Jerzy Gawor, DVM, PhD, DipAVDC/EVDC.
Read more »
Dec 5, 2018
Swedencare expanding its operations in Ireland
Swedencare AB announced today it has moved into new, larger premises in Waterford which it has redeveloped to more than double its capacity and expand its workforce presence in Waterford.
Read more »
October 1, 2018
Swedencare AB (publ)
launch new food co-op
with worldwide premium
dog food brand Canagan.
Read more »
April 20, 2018
Remium’s analysis to institutions
Swedencare’s shares buy
benchmark set to 44 SEK
Read more »
Newsletter Sign-Up
Stay up-to-date with the latest investor related news, delivered right to your inbox!
